Phospholipid ionic liquid transdermal penetration enhancer as well as preparation method and application thereof

By designing phospholipid ionic liquid percutaneous agents, using the combination of isooctyl phosphate and organic amines, the problems of limited effects and irritation of traditional percutaneous agents are solved, and the efficient absorption and safe application of drugs are achieved, with a wide range of Clinical prospects.

CN118955556AActive Publication Date: 2024-11-15SHANTOU UNIV MEDICAL COLLEGE
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
CN202410952024.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-16
Publication Date
2024-11-15
Estimated Expiration
2044-07-16

AI Technical Summary

Technical Problem

Traditional percutaneous permeability agents have limited effect in improving the skin absorption of drugs, and there are skin irritation and uncertainty, which limits their clinical application.

Method used

Develop a phospholipid ionic liquid percutaneous accelerator, through the combination of anions and cations, select isooctyl phosphate as anion and organic amine as cations, and design with low lattice energy and good biocompatibility. A new permeability agent, the effect is verified by Franz diffusion tank.

Benefits of technology

This phospholipid ionic liquid permeability enhancer significantly improves the percutaneous absorption of the drug, has no skin irritation and stability, and has broad application prospects. It can select different concentrations and structures according to needs, and is suitable for the clinical needs of different drugs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004947491140000021
    Figure BDA0004947491140000021
  • Figure BDA0004947491140000022
    Figure BDA0004947491140000022
  • Figure BDA0004947491140000061
    Figure BDA0004947491140000061
Patent Text Reader

Abstract

The invention relates to a phospholipid ionic liquid percutaneous penetration enhancer as well as a preparation method and application thereof, and relates to the technical field of medicines. The phospholipid ionic liquid transdermal penetration enhancer comprises an organic salt, the organic salt is formed by combining anions and cations through coulomb attraction, the anions comprise isooctyl phosphate, and the cations comprise organic amine. The phospholipid ionic liquid percutaneous penetration enhancer has the characteristics of no skin irritation, low lattice energy, good stability and the like, can significantly promote the percutaneous absorption of drugs, and has wide application prospects through the dual effects of promoting the distribution of the drugs to the skin and changing the barrier function of the skin.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of medical technology, in particular to a phospholipid ionic liquid transdermal penetration enhancer and a preparation method and application thereof. Background Art

[0002] Transdermal drug delivery system (TDDS) delivers drugs through the skin into the systemic circulation to exert therapeutic effects. It has the advantages of avoiding gastrointestinal enzymatic hydrolysis and the "first-pass effect" of the liver, convenient administration, and controllable blood drug concentration. It is increasingly valued in the medical field. During transdermal drug delivery, the drug must first pass through the highly ordered and dense intercellular lipid region of the stratum corneum, then distribute into the relatively hydrophilic active epidermis, and then further distribute into the aqueous dermis for absorption into the systemic circulation. Therefore, the transdermal permeation of most drugs is difficult to meet the needs of clinical treatment. The development of a safe and efficient transdermal penetration-enhancing technology is an urgent task for the promotion and application of TDDS.

[0003] Transdermal penetration enhancer (TPE) is the first choice to improve drug skin absorption, but the penetration enhancement effect of TPE sometimes fails to be significantly improved, and most TPEs have not been clinically applied. The reason is that, on the one hand, traditional TPE has penetration enhancement specificity, and its penetration enhancement efficiency is closely related to the physicochemical properties of the drug, mainly due to the difference in the strength of drug-penetration enhancer interaction, which leads to blindness and uncertainty in TPE screening in prescription optimization; on the other hand, the active epidermis of the epidermis contains keratinocytes with different degrees of keratinization, which plays an important role in the initiation and regulation of inflammation, and the irritation / allergic reaction is closely related to the TPE content in the active epidermis, which seriously restricts its clinical application. Therefore, the development of new TPE has important theoretical significance and practical value for the development of TDDS. Summary of the invention

[0004] In view of the above technical problems, the present invention provides a phospholipid ionic liquid transdermal penetration enhancer, which has the characteristics of no skin irritation, low lattice energy, good stability, etc., can significantly promote the transdermal absorption of drugs, and has a dual effect of promoting the distribution of drugs to the skin and changing the skin barrier function, and has broad application prospects.

[0005] The invention provides a phospholipid ionic liquid transdermal penetration enhancer, comprising an organic salt; the organic salt is formed by combining anions and cations through Coulomb attraction, the anions comprise isooctyl phosphate, and the cations comprise organic amines.

[0006] In the process of studying transdermal penetration enhancers, the inventors found that a new type of transdermal penetration enhancer can be designed based on ionic liquids. Ionic liquids refer to organic salts formed by two ions with opposite charges combined by Coulomb attraction, and are in a liquid state below 100°C. The inventors proposed to use the above components as anions and cations. Phospholipids are amphiphilic molecules with a hydrophilic nitrogen or phosphorus tail at one end and a long hydrophobic hydrocarbon chain at the other end. They are important components of biological membranes and have good biocompatibility. Studies have shown that phospholipids can only penetrate 10-15% of the thickness of the stratum corneum, which further indicates that phospholipids have a low potential to cause skin irritation. Therefore, a new type of safe phospholipid-based ionic liquid transdermal penetration enhancer is constructed based on the structure of natural phospholipids. The inventors selected isooctyl phosphate as an anion, which has a melting point of -27°C, a molecular weight of 210.2Da, and no skin irritation. It has a phosphate group and can be used as an anion of a phospholipid ionic liquid, and is easily available. At the same time, organic amines are selected as cations, which are liquids at room temperature, and have a molecular weight of no more than 400Da, so that the sum of the molecular weights of anions and cations does not exceed 600Da. The synthesized permeation enhancer can easily penetrate into the skin to exert its effect and has no skin irritation. The structure contains nitrogen atoms, is alkaline, and can be used as a cation of a phospholipid ionic liquid. Organic amines are safe and easy to obtain. The selection of anions and cations is interdependent. The new ionic liquid transdermal permeation enhancer designed by changing the anions and cations has safe and efficient performance and has broad application prospects.

[0007] In one embodiment, the molar ratio of the anion to the cation is 1:(0.5-1.5).

[0008] In one embodiment, the organic amine includes at least one of triethylamine, tripropylamine, ethanolamine, triethanolamine, and N-lauryldiethanolamine.

[0009] The structural formulas of the above anions and cations are shown below.

[0010]

[0011] The present invention also provides a method for preparing the phospholipid ionic liquid transdermal penetration enhancer, comprising the following steps: adding anions and cations into an organic solvent, reflux stirring, rotary evaporation, removing the solvent, and drying to obtain the phospholipid ionic liquid transdermal penetration enhancer.

[0012] The reaction formula of the above preparation method is as follows:

[0013]

[0014] In the above reaction formula, R is a variable gene of an organic amine. The preparation method has a simple synthesis process, a high yield, a short time, and low requirements on equipment and reaction conditions.

[0015] In one embodiment, the organic solvent includes acetone and / or chloroform.

[0016] In one embodiment, the molar ratio of the anion to the cation is 1:(0.5-1.5).

[0017] In one embodiment, the reflux stirring temperature is 45-55°C, the reflux stirring time is 3-5h, the drying is vacuum drying, and the drying time is 20-30h.

[0018] The invention also provides a transdermal drug delivery system, comprising a drug active ingredient and the phospholipid ionic liquid transdermal penetration enhancer.

[0019] The present invention adopts the Franz diffusion cell method to verify the effect of phospholipid ionic liquid as a permeation enhancer in the above-mentioned transdermal drug delivery system, and selects non-steroidal anti-inflammatory drugs as model drugs, including flurbiprofen, loxoprofen and zaltoprofen. The above-mentioned drugs are used in large doses in clinical practice, and their own skin permeability is low, resulting in an excessively large area of ​​use of the patch. Taking them as research objects has both scientific and practical application value. The experimental results show that the maximum ER values ​​of phospholipid ionic liquids for the three drugs are 6.25, 3.94 and 3.26, respectively, proving that they have good permeation-enhancing effects, and different phospholipid ionic liquids can be selected according to clinical needs.

[0020] In one embodiment, the mass concentration of the phospholipid ionic liquid transdermal penetration enhancer is 5-10%.

[0021] Different concentrations within the above range have a penetration-enhancing effect on the drug.

[0022] The present invention also provides application of the phospholipid ionic liquid transdermal penetration enhancer in drug preparation.

[0023] Compared with the prior art, the present invention has the following beneficial effects:

[0024] The phospholipid ionic liquid transdermal penetration enhancer of the present invention and its preparation method and application, the phospholipid ionic liquid transdermal penetration enhancer has the characteristics of no skin irritation, low lattice energy, good stability, etc., can significantly promote the transdermal absorption of drugs, and has a broad application prospect by promoting the distribution of drugs to the skin and changing the skin barrier function. BRIEF DESCRIPTION OF THE DRAWINGS

[0025] Figure 1 This is the hydrogen spectrum of the nuclear magnetic spectrum of triethylamine isooctyl phosphate in Example 1;

[0026] Figure 2 is the Fourier transform infrared spectrum of triethylammonium isooctyl phosphate of Example 1;

[0027] Figure 3 This is the hydrogen spectrum of the nuclear magnetic spectrum of tripropylamine isooctyl phosphate in Example 2;

[0028] Figure 4 is the Fourier transform infrared spectrum of isooctyl tripropylamine phosphate of Example 2;

[0029] Figure 5 This is the hydrogen spectrum of the nuclear magnetic spectrum of isooctyl ethanolamine phosphate in Example 3;

[0030] Figure 6 is the Fourier transform infrared spectrum of isooctyl ethanolamine phosphate of Example 3;

[0031] Figure 7 This is the hydrogen spectrum of the nuclear magnetic spectrum of triethanolamine phosphate of isooctyl ester in Example 4;

[0032] Figure 8 is the Fourier transform infrared spectrum of isooctyl phosphate triethanolamine of Example 4;

[0033] Fig. 9 This is the hydrogen spectrum of the nuclear magnetic spectrum of N-lauryldiethanolamine phosphate of isooctyl ester in Example 5;

[0034] Fig.10 is the Fourier transform infrared spectrum of isooctyl phosphate N-lauryldiethanolamine of Example 5;

[0035] Fig.11 This is the cumulative permeation diagram of transdermal absorption of flurbiprofen in Experimental Example 1;

[0036] Fig.12 This is the cumulative permeation diagram of loxoprofen transdermal absorption in Experimental Example 1;

[0037] Fig.13 This is the cumulative permeation diagram of zaltoprofen transdermal absorption in Experimental Example 1;

[0038] Fig.14 This is the content of flurbiprofen in plasma in Experimental Example 2;

[0039] Fig.15 This is a graph showing the content of flurbiprofen in the skin in Experimental Example 2;

[0040] Fig.16 This is a graph showing the skin irritation of isooctylethanolamine phosphate in Experimental Example 3. DETAILED DESCRIPTION

[0041] In order to facilitate the understanding of the present invention, the present invention will be described more fully below with reference to the relevant drawings. The preferred embodiments of the present invention are given in the drawings. However, the present invention can be implemented in many different forms and is not limited to the embodiments described herein. On the contrary, the purpose of providing these embodiments is to make the understanding of the disclosure of the present invention more thorough and comprehensive.

[0042] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those generally understood by those skilled in the art of the present invention. The terms used herein in the specification of the present invention are only for the purpose of describing specific embodiments and are not intended to limit the present invention. The term "and / or" used herein includes any and all combinations of one or more related listed items.

[0043] source:

[0044] Unless otherwise specified, the reagents, materials, and equipment used in this example are all commercially available; the experimental methods are all conventional experimental methods in the art unless otherwise specified.

[0045] Example 1

[0046] 0.02 mol of isooctyl phosphate and 0.02 mol of triethylamine were dissolved in 100 ml of acetone, refluxed and stirred at 50° C. for 4 h, the solvent was removed by rotary evaporation, and vacuum dried for 24 h to obtain a light yellow viscous liquid, which is isooctyl phosphate triethylamine ([TEA][IAP]). In this embodiment, the molar ratio of anionic isooctyl phosphate to cationic triethylamine is 1:1.

[0047] The product obtained in this example was subjected to nuclear magnetic resonance hydrogen spectrum and Fourier transform infrared spectrum detection. The hydrogen spectrum and spectrum data obtained are as follows: Figure 1 and Figure 2 As shown, its hydrogen spectrum data is as follows:

[0048] Proton spectrum data: 1H NMR (600 MHz, Chloroform-d) δ7.27 (s, 2H), 3.99–3.77 (m, 2H), 3.76–3.62 (m, 2H), 3.05 (s, 2H), 1.49 (dq, J=12.1, 6.1 Hz, 1H), 1.44–1.12 (m, 11H), 1.01–0.59 (m, 8H).

[0049] Example 2

[0050] 0.02 mol of isooctyl phosphate and 0.02 mol of tripropylamine were dissolved in 100 ml of acetone, refluxed and stirred at 50° C. for 4 h, the solvent was removed by rotary evaporation, and vacuum dried for 24 h to obtain a light yellow viscous liquid, which is isooctyl phosphate tripropylamine ([TPA][IAP]). In this embodiment, the molar ratio of anionic isooctyl phosphate to cationic tripropylamine is 1:1.

[0051] The product obtained in this example was subjected to nuclear magnetic resonance hydrogen spectrum and Fourier transform infrared spectrum detection. The hydrogen spectrum and spectrum data obtained are as follows: Figure 3 and Figure 4 As shown, its hydrogen spectrum data is as follows:

[0052] Proton spectrum data: 1H NMR (600 MHz, Chloroform-d) δ 6.27 (s, 2H), 3.96–3.60 (m, 2H), 3.14–2.65 (m, 5H), 1.68 (dq, J = 11.8, 7.2 Hz, 5H), 1.44 (dq, J = 10.1, 5.8 Hz, 1H), 1.35 (tdd, J = 10.0, 9.4, 7.5, 4.6 Hz, 2H), 1.31–1.14 (m, 9H), 0.97–0.66 (m, 14H).

[0053] Example 3

[0054] 0.02 mol of isooctyl phosphate and 0.02 mol of ethanolamine were dissolved in 100 ml of acetone, refluxed and stirred at 50° C. for 4 h, the solvent was removed by rotary evaporation, and vacuum dried for 24 h to obtain a brown viscous liquid, which is isooctyl phosphate ethanolamine ([EOA][IAP]). In this embodiment, the molar ratio of anionic isooctyl phosphate to cationic ethanolamine is 1:1.

[0055] The product obtained in this example was subjected to nuclear magnetic resonance hydrogen spectrum and Fourier transform infrared spectrum detection. The hydrogen spectrum and spectrum data obtained are as follows: Figure 5 and Figure 6 As shown, its hydrogen spectrum data is as follows:

[0056] Proton spectrum data: 1H NMR (600 MHz, Chloroform-d) δ7.13 (s, 2H), 3.88 (s, 2H), 3.71 (dtd, J = 15.9, 10.7, 10.1, 5.3 Hz, 1H), 3.13 (s, 2H), 1.44–1.12 (m, 5H), 1.01–0.67 (m, 4H).

[0057] Example 4

[0058] 0.02 mol of isooctyl phosphate and 0.02 mol of triethanolamine were dissolved in 100 ml of acetone, refluxed and stirred at 50° C. for 4 h, the solvent was removed by rotary evaporation, and vacuum dried for 24 h to obtain a light yellow viscous liquid, which is isooctyl phosphate triethanolamine ([TEOA][IAP]). In this embodiment, the molar ratio of anionic isooctyl phosphate to cationic triethanolamine is 1:1.

[0059] The product obtained in this example was subjected to nuclear magnetic resonance hydrogen spectrum and Fourier transform infrared spectrum detection. The hydrogen spectrum and spectrum data obtained are as follows: Figure 7 and Figure 8 As shown, its hydrogen spectrum data is as follows:

[0060] Proton spectrum data: 1H NMR (600MHz, Chloroform-d) δ6.36 (s, 5H), 3.89 (s, 5H), 3.71 (s, 2H), 3.53 (d, J = 4.9 Hz, 0H), 3.32 (s, 5H), 1.49 (d, J = 18.1 Hz, 1H), 1.39 (dt, J = 11.5, 7.0 Hz, 1H), 1.36–1.12 (m, 8H), 0.88 (h, J = 6.9 Hz, 7H).

[0061] Example 5

[0062] 0.02 mol of isooctyl phosphate and 0.02 mol of N-lauryl diethanolamine were dissolved in 100 ml of acetone, refluxed and stirred at 50° C. for 4 h, the solvent was removed by rotary evaporation, and vacuum dried for 24 h to obtain a light yellow viscous liquid, which is isooctyl phosphate N-lauryl diethanolamine ([LDEOA][IAP]). In this embodiment, the molar ratio of anionic isooctyl phosphate to cationic-lauryl diethanolamine is 1:1.

[0063] The product obtained in this example was subjected to nuclear magnetic resonance hydrogen spectrum and Fourier transform infrared spectrum detection. The hydrogen spectrum and spectrum data obtained are as follows: Fig. 9 and Fig.10 As shown, its hydrogen spectrum data is as follows:

[0064] Proton spectrum data: 1H NMR (600 MHz, Chloroform-d) δ 6.52 (s, 2H), 3.94–3.62 (m, 3H), 3.62–3.36 (m, 1H), 3.04 (q, J = 7.2 Hz, 7H), 1.54–1.44 (m, 2H), 1.44–1.34 (m, 3H), 1.34–1.09 (m, 24H), 0.98–0.70 (m, 12H).

[0065] Experimental Example 1

[0066] Example 1-5 In vitro transdermal permeation experiments of three drugs using phospholipid ionic liquid transdermal permeation enhancers.

[0067] 1. Experimental methods

[0068] Male Wistar rats (200±20 g) were taken and anesthetized with 20% urethane, and the long hair on the abdomen was cut short with a pet trimmer, and the fine hair was shaved with an electric shaver. The rats were killed by cervical dislocation, and the abdominal skin was peeled off. The subcutaneous fat and connective tissue were removed with surgical scissors, and impurities were wiped off with absorbent cotton and distilled water, and stored in a -70℃ refrigerator for use.

[0069] A Franz horizontal diffusion cell was used, and the mouse skin was installed between the supply cell and the receiving cell, with the stratum corneum facing the supply cell. 4 mL of 1% drug (flurbiprofen, loxoprofen or zaltoprofen) and 10% phospholipid ionic liquid transdermal penetration enhancer caprylic decanoic acid glyceride solution was added to the supply cell of the experimental group, and 4 mL of 1% drug (flurbiprofen, loxoprofen or zaltoprofen) caprylic decanoic acid glyceride solution was added to the supply cell of the blank group. 4 mL of phosphate buffer (pH 7.4) was added to each group of receiving cells. A stirring bar was added to the supply cell and the receiving cell, and the speed was set to 600 rpm / min, and the system temperature was 32°C. After adding the sample, the timing was started, and 2 mL of the receiving solution was taken at 2, 4, 6, and 8 hours, respectively, and an equal amount of isothermal phosphate buffer (pH 7.4) was added at the same time. The sample was centrifuged at 16000 rpm / min for 6 minutes, and the supernatant was analyzed by ultra-high performance liquid chromatography to calculate the cumulative permeation of the drug in 8 hours.

[0070] 2. Experimental results.

[0071] Example 1-5 Effect of phospholipid ionic liquid transdermal penetration enhancers on the in vitro permeation behavior of flurbiprofen, loxoprofen and zaltoprofen. The results are as follows: Fig.11 , Fig.12 and Fig.13 shown.

[0072] Conclusion: 8 hours after administration, Example 3 has the best penetration-enhancing effect on flurbiprofen, loxoprofen and zaltoprofen, and the penetration-enhancing ratios are 6.25, 3.94 and 3.26, respectively.

[0073] Experimental Example 2

[0074] Examples 3 and 5 are experiments on the tissue distribution of flurbiprofen using phospholipid ionic liquid transdermal penetration enhancers.

[0075] 1. Experimental methods

[0076] Male Kunming mice (20±2g) were randomly divided into 12 groups (n=5) at the dosing time points of 2, 4, 6, and 8 hours, and the abdomen was shaved 24 hours in advance. The abdomen of the mice in the experimental group was given 200μL of 1% drug and 10% phospholipid ionic liquid transdermal penetration enhancer caprylic acid glyceride solution, and the abdomen of the mice in the blank group was given 200μL of 1% drug caprylic acid glyceride solution. After the predetermined time point, the preparation was removed, the skin was wiped with methanol and water respectively, the eyeballs of the mice were removed to collect blood and killed, and the skin of the dosing part was cut with surgical scissors. The mouse plasma and skin samples were pre-treated respectively, and the drug concentration was determined by ultra-high performance liquid chromatography.

[0077] 2. Experimental results.

[0078] Results Fig.14 , Fig.15 , the data are shown in Table 1.

[0079] Table 1 Tissue distribution data of blank group, Example 3 and Example 5

[0080]

[0081] Conclusion: After the treatment of Example 3, the drug content of flurbiprofen in plasma, skin and muscle was the highest, which was consistent with the results of the in vitro transdermal test.

[0082] Experimental Example 3

[0083] Example 3 Acute skin irritation test of phospholipid ionic liquid transdermal penetration enhancer.

[0084] 1. Experimental methods

[0085] Self-control method was adopted, and male rabbits (2±0.5kg) were used as model animals. 24h before the test, the hair on both sides of the back spine of the rabbits was shaved. Four administration areas were obtained for each rabbit, and the hair removal range of each area was 3cm×3cm, and the administration area was 2.5cm×2.5cm. The blank control group was not treated in any way, the positive control group was given 0.5mL 10% sodium lauryl sulfate, the negative control group was given 0.5mL octyl decanoate glyceride, and the experimental group was given 0.5mL 10% octyl decanoate glyceride solution of Example 3. After administration, the skin was covered and sealed with gauze and cellophane, and then fixed with medical anti-allergic adhesive tape. The administration time was 8h, and the residue on the skin surface was wiped off with warm water after the application.

[0086] The skin reaction at the application site was observed and scored 1, 24, 48 and 72 hours after the removal of the reagent: when severe erythema (purple-red) to mild eschar formation or severe edema (skin protrusion exceeding 1 mm and expanding range) appeared at the skin application site, 4 points were recorded respectively; when moderate to severe erythema or moderate edema (skin protrusion of about 1 mm) appeared, 3 points were recorded respectively; when obvious erythema or mild edema (skin protrusion with clear outline) appeared, 2 points were recorded respectively; when mild erythema or edema (barely visible) appeared, 1 point was recorded respectively; finally, a comprehensive evaluation was made based on the average score of the test animals. The intensity of skin irritation is determined based on the highest integral mean value among the three observation time points of 24, 48 and 72 hours. When the integral mean value is 6.0-8.0, the result is strong irritation; when the integral mean value is 2.0-<6.0, the result is moderate irritation; when the integral mean value is 0.5-<2.0, the result is light irritation; when the integral mean value is 0-<0.5, the result is non-irritating.

[0087] 2. Experimental results.

[0088] The test results are shown in Fig.16 , the data are shown in Table 2.

[0089] Conclusion: As shown in Table 2, according to the highest mean scores at 24, 48 and 72 hours, the highest mean scores of the positive control, negative control, experimental group and blank control were 6.25, 0, 0.25 and 0, respectively, which means that the positive control was a strong irritant, while the experimental group, blank control and negative control had no obvious irritation. Fig.16 It can be seen that the positive control group has obvious erythema, edema and even scabs, proving that the animal's skin can respond to stimulation. The positive control is highly irritating, while the experimental group, blank control and negative control have no obvious irritation and can maintain a healthy level.

[0090] Table 2 Results of acute skin irritation test in rabbits

[0091]

[0092]

[0093] The technical features of the above-described embodiments may be arbitrarily combined. To make the description concise, not all possible combinations of the technical features in the above-described embodiments are described. However, as long as there is no contradiction in the combination of these technical features, they should be considered to be within the scope of this specification.

[0094] The above-mentioned embodiments only express several implementation methods of the present invention, and the descriptions thereof are relatively specific and detailed, but they cannot be understood as limiting the scope of the invention patent. It should be pointed out that, for ordinary technicians in this field, several variations and improvements can be made without departing from the concept of the present invention, and these all belong to the protection scope of the present invention. Therefore, the protection scope of the patent of the present invention shall be subject to the attached claims.

Claims

1. A phospholipid ionic liquid transdermal penetration enhancer, It is characterized in that It comprises an organic salt; the organic salt is formed by combining anions and cations through Coulomb attraction, the anions comprise isooctyl phosphate, and the cations comprise organic amines.

2. The phospholipid ionic liquid transdermal penetration enhancer according to claim 1, It is characterized in that The molar ratio of the anion to the cation is 1:(0.5-1.5).

3. The phospholipid ionic liquid transdermal penetration enhancer according to claim 1, It is characterized in that The organic amine includes at least one of triethylamine, tripropylamine, ethanolamine, triethanolamine, and N-lauryldiethanolamine.

4. A method for preparing the phospholipid ionic liquid transdermal penetration enhancer according to any one of claims 1 to 3, It is characterized in that The method comprises the following steps: adding anions and cations into an organic solvent, refluxing and stirring, rotary evaporating, removing the solvent, and drying to obtain a phospholipid ionic liquid transdermal penetration enhancer.

5. The preparation method according to claim 4, It is characterized in that The organic solvent includes acetone and / or chloroform.

6. The preparation method according to claim 4, It is characterized in that The molar ratio of the anion to the cation is 1:(0.5-1.5).

7. The preparation method according to claim 4, It is characterized in that The temperature of the reflux stirring is 45-55° C., the time of the reflux stirring is 3-5 h, the drying is vacuum drying, and the drying time is 20-30 h.

8. A transdermal drug delivery system, It is characterized in that The invention comprises a pharmaceutically active ingredient and the phospholipid ionic liquid transdermal penetration enhancer according to any one of claims 1 to 3.

9. The transdermal drug delivery system according to claim 8, It is characterized in that The mass concentration of the phospholipid ionic liquid transdermal penetration enhancer is 5-10%.

10. Use of the phospholipid ionic liquid transdermal penetration enhancer according to any one of claims 1 to 3 in the preparation of drugs.

Citation Information

Patent Citations

  • Quaternary ammonium class ionic liquid compound containing hydroxy groups and preparation method thereof

    CN102659834A

  • Isopulegol fatty acid ester and transdermal drug delivery preparation containing such compound as absorption penetration enhancer

    CN103319336A

  • Room temperature ionic liquid and its preparation method

    CN1785524A

  • Composition for transdermal administration containing resedronate by iontophoresis

    KR1020110100944A

  • Topical composition

    US5015471A